email article
The oral JAK inhibitor upadacitinib (Rinvoq), approved for use in rheumatoid arthritis, also showed promise for psoriatic arthritis in a phase III trial comparing the drug with placebo and adalimumab (Humira).
At week 12, 20% improvements on the criteria of the American College of Rheumatology (ACR20) were seen in 70.6% of patients receiving 15 mg daily of upadacitinib; 78.5% of those given 30 mg per day; 65% of those receiving subcutaneous adalimumab, 40 mg every other week; and 36.2% of those assigned to placebo, reported Iain B. McInnes, MD, PhD, of the University of Glasgow in Scotland, and colleagues.
Both upadacitinib doses were noninferior to adalimumab on the ACR20 criteria, and the 30 mg dose was superior, the investigators reported in the study online in the
email article
Public health scientists and officials shared information about ways to increase uptake of COVID-19 vaccines and reduce vaccine hesitancy, during a hearing of the House Committee on Science, Space and Technology on Friday. The key focus included strategies to eliminate hassles; leverage effective, targeted messaging; and engage trusted communicators.
Committee chair Rep. Eddie Bernice Johnson (D-Texas) warned that vaccine hesitancy could delay the U.S. recovery from the COVID-19 pandemic: We simply cannot and will not bring this virus to an end unless we vaccinate a high percentage of the American population and in fact, the globe, she stressed.
This article is a collaboration between MedPage Today and:
A fourth of previously treated cholangiocarcinomas (CCA) responded to a tyrosine kinase inhibitor (TKI) targeting the fibroblast growth factor receptor (FGFR) family, a phase II open-label study showed.
Confirmed objective responses occurred in 25 of 108 patients treated with infigratinib. Including unconfirmed responses increased the response rate to 34.2%. More than 80% of patients obtained disease control with FGFR inhibitor. Patients who had received no more than one prior systemic therapy responded better, but median progression-free survival (PFS, 7.3-7.4 months) was similar across prior lines of treatment.
Mechanism-based adverse events (AEs) predominated in the safety profile, notably hypophosphatemia and eye disorders, reported Milind Javle, MD, of the MD Anderson Cancer Center in Houston, at the Gastrointestinal Cancers Symposium virtual meeting.